9.31
-0.32%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pulike Biological Engineering
Its shares trade on Shanghai under the ticker 603566.SS. It has been listed since 18 May 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.09bn and net income of CN¥185.0m. At that date it held total assets of CN¥3.24bn and shareholders' equity of CN¥2.61bn.
Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 May 2015
- Employees
- 1,718
- Website
- pulike.com.cn ↗
Leadership
Pay as last reported
- Mr. Xuke ZhangChairman of the Board
- Mr. Dechao QinVice Chairman of the Board, since 2016
- Ms. Lianfeng PeiChief Financial Officer, Director
- Mr. Wei HuGeneral Manager, Director, since 2020
- Mr. Yongjun SongDeputy General Manager, Director, since 2016
- Ms. Bing HanDeputy General Manager
- Mr. Kegong TianDeputy General Manager
- Mr. Rui ZhaoSecretary of the Board, Director, since 2016
- Mr. Yongchang CaoIndependent Director
- Mr. Chuduan WangIndependent Director
- Mr. Xiansheng ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pulike Biological Engineering employs 1718 full-time staff members in Luoyang.
- The company manufactures veterinary biological products for poultry and livestock.
- Chemical drugs treat epidemic diseases in livestock and poultry effectively.
Weaknesses
- The firm is headquartered in Luoyang, Henan, China.
- Pulike Biological Engineering Inc listed its shares on 18 May 2015.
- Chinese veterinary drugs are part of the company's product portfolio.
Opportunities
- Vaccine and antibody products prevent infection in poultry and livestock.
- Research and development drive innovation in biological products for animals.
- Distribution of chemical medicines expands market reach for epidemic treatment.
Threats
- Epidemic diseases pose significant risks to poultry and livestock health.
- Infection control challenges affect the efficacy of veterinary biological products.
- Market competition impacts the sales of chemical drugs and vaccines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.